Sooraj Baijnath1, Nerolen Soobryan2, Irene Mackraj2, Prem Gathiram2, Jagidesa Moodley3. 1. Department of Physiology, University of KwaZulu-Natal, Durban, South Africa. Electronic address: Baijnath.sooraj@gmail.com. 2. Department of Physiology, University of KwaZulu-Natal, Durban, South Africa. 3. Department of Obstetrics and Gynaecology and Women's Health and HIV Research Group, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Abstract
OBJECTIVES: In order to address the gap in our understanding of the pathogenesis and pathophysiology of PE, we optimized the NOS inhibition animal model by comparing changes in different parameters at various time frames during pregnancy, in both early and late-onset PE. STUDY DESIGN: 120 nulliparous Sprague-Dawley rats were divided into 5 groups (n=24). A pregnant control, two groups that represented early and late-onset PE and two groups that were treated with sildenafil citrate (SC) to show reversal of the pre-eclamptic-like symptoms. RESULTS: Our results showed that treatment with L-NAME caused significant changes in physiological parameters for both early and late-onset PE groups. There was a significant increase in systolic blood pressure (SBP) levels in the early-onset PE group (128.5±5.71 mmHg) and late-onset PE group (128.3±6.15 mmHg) on day 19 compared to the SBPs on day 0, (p<0.01). Urine excretion volumes in the early-onset PE group (13.62±3.18 mL) and in the late-onset PE (13.28±2.60 mL), compared to the pregnant control group (11.96±1.9 mL) were also increased (p<0.05). There was also an increase in total urinary protein in the early-onset PE group (0.62±0.08 g/L and the late-onset PE group (0.45±0.05 g/L), when compared to the pregnant control group (0.38±0.07) (p<0.05). We also found a decrease in fetal numbers in the PE group in comparison to the pregnant control and SC treated groups. The remission of these signs was seen after delivery of the fetuses. We also demonstrated that treatment of this syndrome with SC prevented the development of these signs. CONCLUSIONS: The NOS inhibition model can be used for the study of the pathogenesis and pathophysiology of PE, since the pathogenic changes mimic those of early and late-PE.
OBJECTIVES: In order to address the gap in our understanding of the pathogenesis and pathophysiology of PE, we optimized the NOS inhibition animal model by comparing changes in different parameters at various time frames during pregnancy, in both early and late-onset PE. STUDY DESIGN: 120 nulliparous Sprague-Dawley rats were divided into 5 groups (n=24). A pregnant control, two groups that represented early and late-onset PE and two groups that were treated with sildenafil citrate (SC) to show reversal of the pre-eclamptic-like symptoms. RESULTS: Our results showed that treatment with L-NAME caused significant changes in physiological parameters for both early and late-onset PE groups. There was a significant increase in systolic blood pressure (SBP) levels in the early-onset PE group (128.5±5.71 mmHg) and late-onset PE group (128.3±6.15 mmHg) on day 19 compared to the SBPs on day 0, (p<0.01). Urine excretion volumes in the early-onset PE group (13.62±3.18 mL) and in the late-onset PE (13.28±2.60 mL), compared to the pregnant control group (11.96±1.9 mL) were also increased (p<0.05). There was also an increase in total urinary protein in the early-onset PE group (0.62±0.08 g/L and the late-onset PE group (0.45±0.05 g/L), when compared to the pregnant control group (0.38±0.07) (p<0.05). We also found a decrease in fetal numbers in the PE group in comparison to the pregnant control and SC treated groups. The remission of these signs was seen after delivery of the fetuses. We also demonstrated that treatment of this syndrome with SC prevented the development of these signs. CONCLUSIONS: The NOS inhibition model can be used for the study of the pathogenesis and pathophysiology of PE, since the pathogenic changes mimic those of early and late-PE.
Authors: Jose Sergio Possomato-Vieira; Victor Hugo Gonçalves-Rizzi; Tamiris Uracs Sales Graça; Regina Aparecida Nascimento; Carlos A Dias-Junior Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2016-09-12 Impact factor: 3.000
Authors: Regina A Nascimento; Jose S Possomato-Vieira; Giselle F Bonacio; Elen Rizzi; Carlos A Dias-Junior Journal: Cells Date: 2019-11-07 Impact factor: 6.600
Authors: Margarita L Martinez-Fierro; Idalia Garza-Veloz; Maria Eugenia Castañeda-Lopez; Dorothy Wasike; Claudia Castruita-De la Rosa; Iram Pablo Rodriguez-Sanchez; Ivan Delgado-Enciso; Jose Flores-Mendoza Journal: Int J Mol Sci Date: 2022-09-04 Impact factor: 6.208